Navigation Links
Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
Date:9/16/2009

BERLIN, Sept. 17 /PRNewswire/ -- Bayer HealthCare today announced that data from more than 30 clinical trials evaluating three products in the company's oncology portfolio - Nexavar(R) (sorafenib) tablets, regorafenib (BAY 73-4506) and Alpharadin(TM) - will be presented at the joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress, September 20-24, 2009 in Berlin, Germany.

"Bayer is committed to discovering and developing innovative cancer-fighting therapies, and as a global organization with widespread reach and impact, we are able to apply our experience, knowledge and passion to offer treatments that may make life better for cancer patients across the globe," said Rob Rosen, Head of the Therapeutic Area Oncology at Bayer HealthCare. "While much progress has been made in the treatment of cancer, there is still an unmet medical need for improved therapies that may help patients manage their disease, ultimately treating cancer as a chronic illness, rather than a devastating disease."

Nexavar Data Highlights

Nexavar is currently approved in more than 80 countries for the treatment of patients with hepatocellular carcinoma (HCC), or liver cancer, and in more than 90 countries for the treatment of patients with advanced renal cell carcinoma (RCC), or kidney cancer. Even though these indications are well established, the utility of Nexavar continues to be evaluated in these tumor types, with ongoing studies examining special patient populations and long-term use. Data on these indications being presented at ECCO-ESMO include results from two Phase III studies evaluating Nexavar in HCC and six studies examining Nexavar in RCC.

In addition to its current indications, Nexavar continues to be evaluated as a single agent or combination treatment in a wide range of cancers, including
'/>"/>

SOURCE Bayer HealthCare
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
2. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
3. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
4. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
5. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
6. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
7. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
8. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
9. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
10. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
11. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Calif. , July 31, 2014 Lazarus ... of novel interventional devices to facilitate removal of blood ... Proceeds from the financing will support EU commercialization of ... filings for the Lazarus ReCover™ and Lazarus Cover™ in ... "This financing reflects investor confidence in the value of ...
(Date:7/31/2014)... VIENNA , July 31, 2014 ... New York results of AFF008, a ... disease. PD01A is the first therapy against the protein alpha-synuclein, ... The Michael J. Fox Foundation for Parkinson,s Research (MJFF) ... presented at the press conference on the impact a disease-modifying ...
(Date:7/31/2014)... , July 31, 2014 Astellas has ... of corporate and employee communications in the Americas ... Winton , senior vice president, chief communications officer. ... developing and leading corporate brand initiatives and reputation ... North and South America . ...
Breaking Medicine Technology:Lazarus Effect Closes $5 Million Financing 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4Astellas Hires Industry Veteran Moyra Knight as Head of Corporate and Employee Communications 2
... WORTH, Texas, Aug. 24, 2011 The UNT System Board ... authorized in the 82nd Texas legislative session. As part of ... and UNT Dallas, the College of Pharmacy students will earn ... graduate portion of their classes on the UNT Health Science ...
... Technologies, Inc. ( www.heartsine.com ), a world leader in ... the samaritan ® PAD 300P Public Access ... a school serving children and young people with intellectual ... (AED) is now available for Camphill staff enabling ...
Cached Medicine Technology:UNT Regents Approve New College of Pharmacy 2HeartSine® Technologies Donates Lifesaving AED to Camphill Special School 2
(Date:8/1/2014)... US (PRWEB) August 01, 2014 Get ... in partnership with PitchBook presents the 3Q 2014 Private ... U.S private equity investment, exits and fundraising activity in ... insight to help plan for private equity endeavors for ... registration form to download it now. , About Merrill ...
(Date:7/31/2014)... California (PRWEB) July 31, 2014 Serious ... Dead Psychedelic Acid Test concert posters. Owsley Bear Stanley, ... logo for the Grateful Dead. According to Hawley, “The ... to promote acid test parties in San Francisco and ... were printed on three different colors of paper. They ...
(Date:7/31/2014)... Atlanta, GA (PRWEB) July 31, 2014 ... construction camera on its Ponce City Market project ... the historic Sears, Roebuck & Company building into best-in-class ... nears completion, OxBlue reviewed Jamestown’s experience with their construction ... needs. , Jamestown wanted a construction camera ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 United Theological ... 9 a.m. on Monday, September 15, with its 2014 ... Church, 3440 Shroyer Rd., Kettering, OH. Dr. Emma ... in the Emma Toussant Chair will speak on “Unexpected ... Dr. Justes’ teaching and research interests include pastoral care ...
(Date:7/31/2014)... In today’s world, a good night’s sleep ... and sleep apnea (a medical problem where the airway collapses ... partners of the rest they need to face their daily ... and 20 million people in the United States alone have ... treated; and of those treated, many cannot tolerate their prescribed ...
Breaking Medicine News(10 mins):Health News:Register to Download Merrill DataSite's Report: PitchBook 3Q 2014 Private Equity Breakdown Report 2Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 2Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 3Health News:United Theological Seminary to Open 144th Year 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... News) -- Successful treatment of major depression in mothers also ... a new study. Children of parents with major depression ... This study included 80 women with depression and their ... a U.S. National Institute of Mental Health trial designed to ...
... Scientists have shown that an experimental vaccine against the human ... contagious nonbacterial illnesses that cause diarrhea and vomiting can ... cause the animals any harm. Using a novel viral ... shown promise in other agents designed to fight such infections ...
... the first laparoscopic procedure was performed to remove a ... St. Louis, this breakthrough minimally invasive technique has become ... achievement is celebrated with a series of cutting-edge articles ... published by Mary Ann Liebert, Inc. ( www.liebertpub.com ). ...
... considered a safe procedure, although complications can occur. The ... reports perforation rates of 0.03%-0.8% for diagnostic procedures, and ... perforation are the result of either mechanical disruption of ... a diverticulum, or stretching of the bowel with loops ...
... successfully treated for depression are at higher risk of losing ... study in the March 15, 2011 issue of the journal ... third of those who experience a stroke develop depression, a ... of health and rehabilitation sciences and of medicine at Indiana ...
... Ben-Gurion University of the Negev (BGU) researchers have shown that ... may have Obstructive Sleep Apnea (OSA), which may be the ... study compared men between the ages of 55 and 75 ... BPE and reported nocturia at least once nightly. The comparison ...
Cached Medicine News:Health News:New vaccine candidate shows strong potential to prevent highly contagious norovirus 2Health News:New vaccine candidate shows strong potential to prevent highly contagious norovirus 3Health News:New vaccine candidate shows strong potential to prevent highly contagious norovirus 4Health News:20th anniversary of first laparoscopic nephrectomy 2Health News:Managing post-stroke depression improves physical functioning 2Health News:Managing post-stroke depression improves physical functioning 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: